Purespring Therapeutics
PrivateLast Round
Series B
Oct 9, 2024
Est. Valuation
$176.4M
Total Funding Raised
$227.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Purespring Therapeutics is a biotechnology company that develops AAV gene therapies to treat kidney diseases by targeting the podocyte.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Purespring Therapeutics Comparables
Compare Purespring Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Walden Biosciences | 77% | |
| Torque Bio, Inc. | 76% | |
| Borealis Biosciences | 72% |
Purespring Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 9, 2024 | ||||
| Series A | Jul 30, 2021 | ||||
| Series A | Nov 19, 2020 |
Key People
Founding team and executive leadership
Purespring Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| Syncona | Series B, Series A |
| British Patient Capital | Series B |
| Gilde Healthcare | Series B |
| Sofinnova Partners | Series B |
| Syncona Limited | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 44% MoM.
- Jun 19, 2026
Monthly visitors increased 151% MoM, reaching 2.7K.
Recent news
Latest coverage and updates
- attends_eventOct 27, 2026
Purespring Therapeutics Limited attends ASN Kidney Week 2026, where new preclinical and epidemiological data on kidney-targeted gene therapy PS-003 are presented.
Purespring Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Purespring Therapeutics's valuation, stock price, and market status.
Is Purespring Therapeutics a public or private company?
Purespring Therapeutics is a private company.
What is the current stock price of Purespring Therapeutics?
Purespring Therapeutics is a private company, so its shares have no public market price. Caplight tracks Purespring Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Purespring Therapeutics worth (valuation)?
Purespring Therapeutics's valuation is estimated at $176.4M based on funding round data.
Can I buy Purespring Therapeutics stock?
Purespring Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Purespring Therapeutics's last funding round?
Purespring Therapeutics's most recent funding round was Series B on October 9, 2024.
Who are the main investors in Purespring Therapeutics?
Key investors in Purespring Therapeutics include Syncona, Sofinnova Partners.
Will Purespring Therapeutics IPO soon?
No public IPO plans have been announced for Purespring Therapeutics.
How can I track Purespring Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Purespring Therapeutics's shares on secondary markets.